RNS Number : 0831M EKF Diagnostics Holdings PLC 12 September 2023

# **EKF Diagnostics Holdings plc**

("EKF", the "Company" or the "Group")

#### Appointment of CFO

E K FDiagnostics Holdings plc (AIM: EKF), theAIM-listed global diagnostic business, announces the appointment of Stephen ("Steve") Young as Chief Financial Officer ("CFO") and to the EKF Board, effective immediately. Steve Young has been working as a consultant at EKF for the last two months alongside the Group's outgoing CFO to affect an orderly handover.

Steve is an experienced Finance Director and CFO and joins the Company from Trellus Health plc ("Trellus") where he has served as Interim Chief Financial Officer, in a non-board capacity, since August 2022.

Prior to working with Trellus, Steve served as CFO and Company Secretary (a non-Director role) with Axiom Manufacturing Limited, a contract electronic manufacturer. Having joined in 2009 when Axiom generated close to £12m in revenue and was loss making, he supported the restructuring of the business to over £62m turnover in 2020. Axiom also acquired Greeve Limited in 2016 where Steve became a Director.

In addition to this, Steve has experience with AIM-quoted businesses having served as CFO at Pure Wafer plc and, before this, BBI Holdings plc ("BBI") which admitted to AIM in 2004. During Steve's seven-year tenure at BBI he reported to EKF Executive Chair Julian Baines when he was CEO of BBI. Steve is a member of the Chartered Institute of Management Accountants (CIMA).

Julian Baines, Executive Chair of EKF, commented:"I'm pleased to welcome Steve Young to the EKF team and to work again with him after doing so at BBI Holdings plc. Steve is a highly dependable and experienced CFO, with a strong working knowledge of how AIM companies operate, so I look forward to his support as we continue to execute against our plans for significant long-term growth."

# Additional Disclosures Required under the AIM Rules for Companies

Stephen Michael Young (aged 60) has held the following directorship or partnerships in the past five years:

#### Current directorships and partnerships:

• N/A

### Previous directorships and partnerships held in the past five years:

• Greeve Limited

Stephen currently holds 85,000 ordinary shares in the Company.

Save as disclosed above, there is no further information to be disclosed in respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.

### **EKF Diagnostics Holdings plc** Julian Baines, Executive Chair

Singer Capital Markets (Nominated Adviser & Broker) Aubrey Powell / George Tzimas / Oliver Platts

Walbrook PR Limited Paul McManus / Lianne Applegarth <u>www.ekfdiagnostics.com</u> Tel: +44 (0)29 2071 0570

Tel: +44 (0)20 7496 3000

Tel: +44 (0)20 7933 8780 or <u>ekf@walbrookpr.com</u> Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

About EKF Diagnostics Holdings plc (<u>www.ekfdiagnostics.com</u>)

EKF is an AIM-listed global diagnostics business focussed on:

- **Point-of-Care** analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges
- Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications, as well as other higher value Contract Manufacturing services

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

BOAGPUMCBUPWPUG